Search filters

List of works by Eva Havrdová

044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)

scholarly article published on 24 May 2018

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study

scientific article published on 2 May 2017

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

scientific article published on 28 February 2019

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients

scientific article published on 16 February 2016

ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II

scientific article published on 14 October 2015

ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS

scientific article published on 15 November 2016

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

scientific article published on 19 October 2011

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

scientific article

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

scientific article

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

scientific article

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

scientific article published on 12 October 2016

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

scientific article published on 24 November 2016

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

scientific article

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

scientific article (publication date: November 2012)

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

scientific article published on 9 August 2017

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes

scientific article published on 27 January 2014

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

scientific article published on 01 January 2019

Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study.

scientific article published on 10 January 2013

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

scientific article

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate

scientific article

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study

scientific article published on 8 June 2013

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

scientific article published on 30 October 2020

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis

scientific article published on 6 April 2016

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients

scientific article published on 06 March 2018

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom ⬇️

journal article from 'PharmacoEconomics' published in 2022

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

scientific article published on 5 December 2014

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

scientific article published on April 2015

Contribution of different relapse phenotypes to disability in multiple sclerosis.

scientific article published on 7 April 2016

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

scientific article

Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

scientific article published on 4 October 2012

DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED

scientific article published on 15 November 2016

DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE

scientific article published on 15 November 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

scientific article published on October 2015

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial ⬇️

scientific article published on April 4, 2013

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

scientific article published in May 2014

Defining reliable disability outcomes in multiple sclerosis

scientific article published on 10 September 2015

Defining secondary progressive multiple sclerosis

scientific article published on 7 July 2016

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

scientific article

Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis

scientific article

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study

scientific article

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

scientific article

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

scientific article published on 15 June 2020

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

scientific article published on 10 September 2013

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

scientific article

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

scientific article published on 29 December 2013

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

scientific article

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

scientific article

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

scientific article

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

scientific article

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

scientific article published in October 2008

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

scientific article

Freedom from disease activity in multiple sclerosis

scientific article

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

scientific article published on 24 January 2009

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders

scientific article published on 22 August 2014

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

scientific article published on 31 May 2011

Health-related quality of life in multiple sclerosis: effects of natalizumab

scientific article

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

scientific article published on 3 November 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

scientific article published on 28 September 2016

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study

scientific article published on 30 April 2014

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

scientific article published on 13 November 2016

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later

scientific article published on 11 September 2015

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

scientific article published on 05 October 2018

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

scientific article published on November 2007

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score

scientific article

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

scientific article published on 2 August 2013

Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis

scientific article published on 01 February 2013

Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosis

scientific article published on 21 August 2012

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

scientific article published on 26 May 2016

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

scientific article published on 17 April 2013

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

scientific article

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

scientific article published on April 2017

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

scientific article

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

scientific article published on 22 June 2014

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

scientific article published on 22 November 2017

Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy

scientific article published in October 2014

MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION

scientific article published on 14 October 2015

MRI correlates of disability progression in patients with CIS over 48 months

scientific article

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

scientific article

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

scientific article published on 09 February 2017

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

scientific article

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis

scientific article published in 2024

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

scientific article

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

scientific article published on 14 February 2018

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

scientific article published on 24 April 2007

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

scientific article published in January 2018

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

scientific article published in December 2016

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me

scientific article published on 24 August 2013

Oral BG-12 in Multiple Sclerosis ⬇️

scientific article published on April 25, 2013

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

scientific article published on 17 March 2009

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis ⬇️

scientific article published on September 20, 2012

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

scientific article published on 4 May 2016

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

scientific article published on 13 July 2016

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

scientific article

Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)

scientific article published on 06 August 2016

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

scientific article published on 24 November 2016

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

scientific article published on 18 February 2019

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

scientific article

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

scientific article published on 10 April 2012

Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies

scientific article published on 30 October 2015

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment

scientific article published on 8 October 2014

Reliable measurements of brain atrophy in individual patients with multiple sclerosis.

scientific article

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]

scientific article published on 24 February 2018

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

scientific article

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

scientific article published on February 2012

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

scientific article

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

scientific article published on 22 January 2014

Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.

scientific article published on August 2008

Serological analysis of complement in patients with neuromyelitis optica

scholarly article by Petra Nytrova et al published November 2012 in Immunobiology

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

scientific article published on 6 December 2016

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study

scientific article published on 17 June 2014

Should rapid decrease of NK cells be marker of conversion from CIS to CDMS?

scientific article published in October 2014

Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).

scientific article

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

scientific article published on 02 September 2016

Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management

scientific article published on 21 January 2018

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

scientific article published on 17 January 2015

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

scientific article

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

scientific article published in November 2014

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

scientific article published on 21 July 2015

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

scientific article published on 29 May 2009

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

scientific article published on 18 March 2009

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

scientific article

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

scientific article

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

scientific article published in September 2017

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

scientific article published on 10 February 2017

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

scientific article published on 16 October 2017

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

scientific article

Case reports multiple sclerosis

book edition published in 2020

Roztroušená skleróza v praxi

book edition published in 2015

Současné trendy v rehabilitaci pacientů s roztroušenou sklerózou ⬇️

book edition published in 2016–

Paulina is supported by:

About Paulina

Help